Therefore, we develop and support various sustainable strategies to improve access in low- and middle-income countries, including directing differential pricing to patient sub-segments, either directly through national or local programs or indirectly through thirdparty health care funding sources that demonstrate reasonable and secure product distribution to intended patient segments and subject to applicable legal requirements.